Methylation of MGMT and ADAMTS14 in normal colon mucosa: Biomarkers of a field defect for cancerization preferentially targeting elder African-Americans

Oncotarget

Volumn 6, Issue 5, 2015, Pages 3420-3431

  Alonso, Sergio ^a,b   Dai, Yuichi ^a,c,d   Yamashita, Kentaro ^a   Horiuchi, Shina ^a   Dai, Tomoko ^a,c   Matsunaga, Akihiro ^a   Sánchez Muñoz, Rosa ^a   Bilbao Sieyro, Cristina ^e   Díaz Chico, Juan Carlos ^e   Chernov, Andrei V ^a   Strongin, Alex Y ^a   Perucho, Manuel ^a,b,f  

^a BURNHAM INSTITUTE   (United States)

^b Institute of Predictive and Personalized Medicine of Cancer (IMPPC) IGTP   (Spain)

^c UNIVERSITY OF TSUKUBA   (Japan)

^d Tsukuba Memorial Hospital   (Japan)

^e UNIVERSITY OF LAS PALMAS DE GRAN CANARIA   (Spain)

^f INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

Author keywords

ADAMTS14; Colorectal cancer; CRC; KRAS mutations; MGMT; O6 methylguanine DNA methyltransferase; TP53 mutations

Indexed keywords

MESSENGER RNA; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; ADAM PROTEIN; ADAMTS PROTEIN; ADAMTS14 PROTEIN, HUMAN; DNA LIGASE; DNA METHYLTRANSFERASE; KRAS PROTEIN, HUMAN; MGMT PROTEIN, HUMAN; PROTEIN P21; PROTEIN P53; TP53 PROTEIN, HUMAN; TUMOR SUPPRESSOR PROTEIN;

ADAMTS14 GENE; AFRICAN AMERICAN; AGE; AGED; ARTICLE; COLON MUCOSA; COLORECTAL CANCER; CONTROLLED STUDY; DNA METHYLATION; EXOME; FEMALE; GENE; GENE SILENCING; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MICROSATELLITE INSTABILITY; MISSENSE MUTATION; NUCLEIC ACID BASE SUBSTITUTION; O6 METHYLGUANINE DNA METHYLTRANSFERASE GENE; ONCOGENE K RAS; RACE DIFFERENCE; SOMATIC MUTATION; TUMOR SUPPRESSOR GENE; ADENOCARCINOMA; COLON; COLORECTAL TUMOR; ENZYMOLOGY; EPIDEMIOLOGY; ETHNOLOGY; GENE EXPRESSION REGULATION; GENETIC DATABASE; GENETIC EPIGENESIS; GENETIC PREDISPOSITION; GENETICS; INTESTINE MUCOSA; MUTATION; PHENOTYPE; RETROSPECTIVE STUDY; RISK FACTOR; UNITED STATES;

ADAM PROTEINS; ADAMTS PROTEINS; ADENOCARCINOMA; AFRICAN AMERICANS; AGE FACTORS; COLON; COLORECTAL NEOPLASMS; DATABASES, GENETIC; DNA METHYLATION; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INTESTINAL MUCOSA; MICROSATELLITE INSTABILITY; MUTATION; PHENOTYPE; PROTO-ONCOGENE PROTEINS P21(RAS); RETROSPECTIVE STUDIES; RISK FACTORS; RNA, MESSENGER; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS; UNITED STATES;

EID: 84923311865     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2852     Document Type: Article

References (59)

1. Ionov Y, Peinado MA, Malkhosyan S, Shibata D, Perucho M. Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis. Nature. 1993; 363:558-561.
2. Boland CR. Roles of the DNA mismatch repair genes in colorectal tumorigenesis. Int J Cancer. 1996; 69:47-49.
3. Kinzler KW, Vogelstein B. Lessons from hereditary colorectal cancer. Cell. 1996; 87:159-170.
4. Black D, Soslow RA, Levine DA, Tornos C, Chen SC, Hummer AJ, Bogomolniy F, Olvera N, Barakat RR, Boyd J. Clinicopathologic significance of defective DNA mismatch repair in endometrial carcinoma. J Clin Oncol. 2006; 24:1745-1753.
5. Kane MF, Loda M, Gaida GM, Lipman J, Mishra R, Goldman H, Jessup JM, Kolodner R. Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines. Cancer Res. 1997; 57:808-811.
6. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet. 2002; 3:415-428.
7. Perucho M. Cancer of the microsatellite mutator phenotype. Biological chemistry. 1996; 377:675-684.
8. Markowitz S, Wang J, Myeroff L, Parsons R, Sun L, Lutterbaugh J, Fan RS, Zborowska E, Kinzler KW, Vogelstein B, et al. Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. Science. 1995; 268:1336-1338.
9. Rampino N, Yamamoto H, Ionov Y, Li Y, Sawai H, Reed JC, Perucho M. Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype. Science. 1997; 275:967-969.
10. Barbacid M. ras oncogenes: their role in neoplasia. Eur J Clin Invest. 1990; 20:225-235.
11. Malumbres M, Barbacid M. RAS oncogenes: the first 30 years. Nat Rev Cancer. 2003; 3:459-465.
12. Bos JL, Fearon ER, Hamilton SR, Verlaan-de Vries M, van Boom JH, van der Eb AJ, Vogelstein B. Prevalence of ras gene mutations in human colorectal cancers. Nature. 1987; 327:293-297.
13. Forrester K, Almoguera C, Han K, Grizzle WE, Perucho M. Detection of high incidence of K-ras oncogenes during human colon tumorigenesis. Nature. 1987; 327:298-303.
14. Prior IA, Lewis PD, Mattos C. A comprehensive survey of Ras mutations in cancer. Cancer Res. 2012; 72:2457-2467.
15. Lane DP. Cancer. p53, guardian of the genome. Nature. 1992; 358:15-16.
16. Russo A, Bazan V, Iacopetta B, Kerr D, Soussi T, Gebbia N. The TP53 colorectal cancer international collaborative study on the prognostic and predictive significance of p53 mutation: influence of tumor site, type of mutation, and adjuvant treatment. J Clin Oncol. 2005; 23:7518-7528.
17. Gerson SL. MGMT: its role in cancer aetiology and cancer therapeutics. Nat Rev Cancer. 2004; 4:296-307.
18. Shuker DE, Margison GP. Nitrosated glycine derivatives as a potential source of O6-methylguanine in DNA. Cancer Res. 1997; 57:366-369.
19. Esteller M, Hamilton SR, Burger PC, Baylin SB, Herman JG. Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res. 1999; 59:793-797.
20. Nakagawachi T, Soejima H, Urano T, Zhao W, Higashimoto K, Satoh Y, Matsukura S, Kudo S, Kitajima Y, Harada H, Furukawa K, Matsuzaki H, et al. Silencing effect of CpG island hypermethylation and histone modifications on O6-methylguanine-DNA methyltransferase (MGMT) gene expression in human cancer. Oncogene. 2003; 22:8835-8844.
21. Esteller M, Toyota M, Sanchez-Cespedes M, Capella G, Peinado MA, Watkins DN, Issa JP, Sidransky D, Baylin SB, Herman JG. Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is associated with G to A mutations in K-ras in colorectal tumorigenesis. Cancer Res. 2000; 60:2368-2371.
22. Esteller M, Risques RA, Toyota M, Capella G, Moreno V, Peinado MA, Baylin SB, Herman JG. Promoter hypermethylation of the DNA repair gene O(6)-methylguanine-DNA methyltransferase is associated with the presence of G:C to A:T transition mutations in p53 in human colorectal tumorigenesis. Cancer Res. 2001; 61:4689-4692.
23. Qi J, Zhu YQ, Huang MF, Yang D. Hypermethylation of CpG island in O6-methylguanine-DNA methyltransferase gene was associated with K-ras G to A mutation in colorectal tumor. World J Gastroenterol. 2005; 11:2022-2025.
24. Shen L, Kondo Y, Rosner GL, Xiao L, Hernandez NS, Vilaythong J, Houlihan PS, Krouse RS, Prasad AR, Einspahr JG, Buckmeier J, Alberts DS, et al. MGMT promoter methylation and field defect in sporadic colorectal cancer. J Natl Cancer Inst. 2005; 97:1330-1338.
25. Shen H, Laird PW. Interplay between the cancer genome and epigenome. Cell. 2013; 153:38-55.
26. Lind GE, Thorstensen L, Lovig T, Meling GI, Hamelin R, Rognum TO, Esteller M, Lothe RA. A CpG island hypermethylation profile of primary colorectal carcinomas and colon cancer cell lines. Mol Cancer. 2004; 3:28.
27. Halford S, Rowan A, Sawyer E, Talbot I, Tomlinson I. O(6)-methylguanine methyltransferase in colorectal cancers: detection of mutations, loss of expression, and weak association with G:C>A:T transitions. Gut. 2005; 54:797-802.
28. Suehiro Y, Wong CW, Chirieac LR, Kondo Y, Shen L, Webb CR, Chan YW, Chan AS, Chan TL, Wu TT, Rashid A, Hamanaka Y, et al. Epigenetic-genetic interactions in the APC/WNT, RAS/RAF, and P53 pathways in colorectal carcinoma. Clin Cancer Res. 2008; 14:2560-2569.
29. Minoo P. Toward a Molecular Classification of Colorectal Cancer: The Role of MGMT. Frontiers in oncology. 2013; 3:266.
30. Cal S, Obaya AJ, Llamazares M, Garabaya C, Quesada V, Lopez-Otin C. Cloning, expression analysis, and structural characterization of seven novel human ADAMTSs, a family of metalloproteinases with disintegrin and thrombospondin-1 domains. Gene. 2002; 283:49-62.
31. Wagstaff L, Kelwick R, Decock J, Edwards DR. The roles of ADAMTS metalloproteinases in tumorigenesis and metastasis. Front Biosci (Landmark Ed). 2011; 16:1861-1872.
32. Przemyslaw L, Boguslaw HA, Elzbieta S, Malgorzata SM. ADAM, and ADAMTS family proteins and their role in the colorectal cancer etiopathogenesis. BMB Rep. 2013; 46:139-150.
33. Fontanil T, Rua S, Llamazares M, Moncada-Pazos A, Quiros PM, Garcia-Suarez O, Vega JA, Sasaki T, Mohamedi Y, Esteban MM, Obaya AJ, Cal S. Interaction between the ADAMTS-12 metalloprotease and fibulin-2 induces tumor-suppressive effects in breast cancer cells. Oncotarget. 2014; 5:1253-1264.
34. The Cancer Genome Atlas Research Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012; 487:330-337.
35. Paun BC, Kukuruga D, Jin Z, Mori Y, Cheng Y, Duncan M, Stass SA, Montgomery E, Hutcheon D, Meltzer SJ. Relation between normal rectal methylation, smoking status, and the presence or absence of colorectal adenomas. Cancer. 2010; 116:4495-4501.
36. Svrcek M, Buhard O, Colas C, Coulet F, Dumont S, Massaoudi I, Lamri A, Hamelin R, Cosnes J, Oliveira C, Seruca R, Gaub MP, et al. Methylation tolerance due to an O6-methylguanine DNA methyltransferase (MGMT) field defect in the colonic mucosa: an initiating step in the development of mismatch repair-deficient colorectal cancers. Gut. 2010; 59:1516-1526.
37. Jackson AL, Loeb LA. The mutation rate and cancer. Genetics. 1998; 148:1483-1490.
38. Loeb LA, Bielas JH, Beckman RA. Cancers exhibit a mutator phenotype: clinical implications. Cancer Res. 2008; 68:3551-3557; discussion 3557.
39. Loeb LA. Human cancers express mutator phenotypes: origin, consequences and targeting. Nat Rev Cancer. 2011; 11:450-457.
40. Winter E, Yamamoto F, Almoguera C, Perucho M. A method to detect and characterize point mutations in transcribed genes: amplification and overexpression of the mutant c-Ki-ras allele in human tumor cells. Proc Natl Acad Sci U S A. 1985; 82:7575-7579.
41. Winter E, Perucho M. Oncogene amplification during tumorigenesis of established rat fibroblasts reversibly transformed by activated human ras oncogenes. Mol Cell Biol. 1986; 6:2562-2570.
42. Finney RE, Bishop JM. Predisposition to neoplastic transformation caused by gene replacement of H-ras1. Science. 1993; 260:1524-1527.
43. Rideout WM 3rd, Coetzee GA, Olumi AF, Jones PA. 5-Methylcytosine as an endogenous mutagen in the human LDL receptor and p53 genes. Science. 1990; 249:1288-1290.
44. Shen JC, Rideout WM 3rd, Jones PA. The rate of hydrolytic deamination of 5-methylcytosine in double-stranded DNA. Nucleic Acids Res. 1994; 22:972-976.
45. Kast RE, Boockvar JA, Bruning A, Cappello F, Chang WW, Cvek B, Dou QP, Duenas-Gonzalez A, Efferth T, Focosi D, Ghaffari SH, Karpel-Massler G, et al. A conceptually new treatment approach for relapsed glioblastoma: coordinated undermining of survival paths with nine repurposed drugs (CUSP9) by the International Initiative for Accelerated Improvement of Glioblastoma Care. Oncotarget. 2013; 4:502-530.
46. Perry C, Agarwal D, Abdel-Fatah TM, Lourdusamy A, Grundy R, Auer DT, Walker D, Lakhani R, Scott IS, Chan S, Ball G, Madhusudan S. Dissecting DNA repair in adult high grade gliomas for patient stratification in the post-genomic era. Oncotarget. 2014; 5:5764-5781.
47. Miyamoto K, Ushijima T. Diagnostic and therapeutic applications of epigenetics. Jpn J Clin Oncol. 2005; 35:293-301.
48. Amatu A, Sartore-Bianchi A, Moutinho C, Belotti A, Bencardino K, Chirico G, Cassingena A, Rusconi F, Esposito A, Nichelatti M, Esteller M, Siena S. Promoter CpG island hypermethylation of the DNA repair enzyme MGMT predicts clinical response to dacarbazine in a phase II study for metastatic colorectal cancer. Clin Cancer Res. 2013; 19:2265-2272.
49. Toyota M, Ahuja N, Ohe-Toyota M, Herman JG, Baylin SB, Issa JP. CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci U S A. 1999; 96:8681-8686.
50. Yamashita K, Dai T, Dai Y, Yamamoto F, Perucho M. Genetics supersedes epigenetics in colon cancer phenotype. Cancer Cell. 2003; 4:121-131.
51. Suzuki K, Suzuki I, Leodolter A, Alonso S, Horiuchi S, Yamashita K, Perucho M. Global DNA demethylation in gastrointestinal cancer is age dependent and precedes genomic damage. Cancer Cell. 2006; 9:199-207.
52. Tammana VS, Laiyemo AO. Colorectal cancer disparities: issues, controversies and solutions. World J Gastroenterol. 2014; 20:869-876.
53. World Medical Association . World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013; 310:2191-2194.
54. Maniatis T, Fritsch EF, Sambrook J. Molecular cloning: a laboratory manual. Cold Spring Harbor, Laboratory Cold Spring Harbor, N.Y: 1982.
55. Yamamoto H, Perez-Piteira J, Yoshida T, Terada M, Itoh F, Imai K, Perucho M. Gastric cancers of the microsatellite mutator phenotype display characteristic genetic and clinical features. Gastroenterology. 1999; 116:1348-1357.
56. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation-specific, PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A. 1996; 93:9821-9826.
57. Clark SJ, Harrison J, Paul CL, Frommer M. High sensitivity mapping of methylated cytosines. Nucleic Acids Res. 1994; 22:2990-2997.
58. Xiong Z, Laird PW. COBRA: a sensitive and quantitative DNA methylation assay. Nucleic Acids Res. 1997; 25:2532-2534.
59. R Development Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing Vienna, Austria: 2009.